Derivation and Validation of a New Cardiovascular Risk Score for People With Type 2 Diabetes The New Zealand Diabetes Cohort Study

被引:67
|
作者
Elley, C. Raina [1 ]
Robinson, Elizabeth [2 ]
Kenealy, Tim [1 ]
Bramley, Dale [3 ]
Drury, Paul L. [4 ]
机构
[1] Univ Auckland, Sch Populat Hlth, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand
[2] Univ Auckland, Sch Populat Hlth, Epidemiol & Biostat Sect, Auckland 1, New Zealand
[3] Waitemata Dist Hlth Board, Auckland, New Zealand
[4] Auckland Dist Hlth Board, Auckland Diabet Ctr, Auckland, New Zealand
关键词
CORONARY-HEART-DISEASE; PREDICTION; POPULATION; EVENTS; DEPRIVATION; PERFORMANCE; HEMOGLOBIN; MORTALITY; OUTCOMES; ENGINE;
D O I
10.2337/dc09-1444
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To derive a 5-year cardiovascular disease (CVD) risk equation from usual-care data that is appropriate for people with type 2 diabetes From a wide range of ethnic groups, variable glycemic control, and high rates of albuminuria in New Zealand. RESEARCH DESIGN AND METHODS - This prospective open-cohort study used primary-care data from 36,127 people with type 2 diabetes without previous CVD to derive a CVD equation using Cox proportional hazards regression models. Data from 12,626 people from a geographically different area were used for validation. Outcome measure was time to first fatal or nonfatal cardiovascular event, derived from national hospitalization and mortality records. Risk factors were age at diagnosis, diabetes duration, sex, systolic blood pressure, smoking status, total cholesterol-to-HDL ratio, ethnicity, glycated hemoglobin (AlC), and urine albumin-to-creatinine ratio. RESULTS - Baseline median age was 59 years, 51% were women, 55% were of non-European ethnicity, and 33% had micro- or macroalbuminuria. Median follow-up was 3.9 years (141,169 person-years), including 10,030 individuals followed for at least 5 years. At total of 6,479 first cardiovascular events occurred during follow-up. The 5-year observed risk was 20.8% (95% Cl 20.3-21.3). Risk increased with each 1% AlC (adjusted hazard ratio 1.06 [95% Cl 1.05-1.08]), when macroalbuminuria was present (2.04 [1.89-2.21]), and in Indo-Asians (1.29 [1.14-1.46]) and Maori (1.23 [1.14-1.32]) compared with Europeans. The derived risk equations performed well on the validation cohort compared with other risk equations. CONCLUSIONS - Renal function, ethnicity, and glycemic control contribute significantly In cardiovascular risk prediction. Population-appropriate risk equations cart be derived from routinely collected data.
引用
收藏
页码:1347 / 1352
页数:6
相关论文
共 50 条
  • [1] Derivation and Validation of a Renal Risk Score for People With Type 2 Diabetes
    Elley, C. Raina
    Robinson, Tom
    Moyes, Simon A.
    Kenealy, Tim
    Collins, John
    Robinson, Elizabeth
    Orr-Walker, Brandon
    Drury, Paul L.
    DIABETES CARE, 2013, 36 (10) : 3113 - 3120
  • [2] An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study
    Davis, W. A.
    Knuiman, M. W.
    Davis, T. M. E.
    INTERNAL MEDICINE JOURNAL, 2010, 40 (04) : 286 - 292
  • [3] External Validation of the UKPDS Risk Engine in Incident Type 2 Diabetes: A Need for New Type 2 Diabetes-Specific Risk Equations
    Bannister, Christian A.
    Poole, Chris D.
    Jenkins-Jones, Sara
    Morgan, Christopher Ll
    Elwyn, Glyn
    Spasic, Irena
    Currie, Craig J.
    DIABETES CARE, 2014, 37 (02) : 537 - 545
  • [4] An association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New Zealand
    Kenealy, T.
    Elley, C. R.
    Robinson, E.
    Bramley, D.
    Drury, P. L.
    Kerse, N. M.
    Moyes, S. A.
    Arroll, B.
    DIABETIC MEDICINE, 2008, 25 (11) : 1302 - 1308
  • [5] Cardiovascular risk stratification in patients with type 2 diabetes
    Grossmann, V.
    Schmitt, V. H.
    Juenger, C.
    Muenzel, T.
    Wild, P. S.
    DIABETOLOGE, 2014, 10 (07): : 572 - 580
  • [6] Cohort study evaluation of New Chinese Diabetes Risk Score: a new non-invasive indicator for predicting type 2 diabetes mellitus
    Zhao, Y.
    Feng, Y.
    Yang, X.
    Li, Y.
    Wu, Y.
    Hu, F.
    Zhang, M.
    Sun, L.
    Hu, D.
    PUBLIC HEALTH, 2022, 208 : 25 - 31
  • [7] Adherence to metformin monotherapy in people with type 2 diabetes mellitus in New Zealand
    Horsburgh, Simon
    Barson, David
    Zeng, Jiaxu
    Sharples, Katrina
    Parkin, Lianne
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 158
  • [8] The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus
    van der Leeuw, J.
    van Dieren, S.
    Beulens, J. W. J.
    Boeing, H.
    Spijkerman, A. M. W.
    van der Graaf, Y.
    van der A, D. L.
    Noethlings, U.
    Visseren, F. L. J.
    Rutten, G. E. H. M.
    Moons, K. G. M.
    van der Schouw, Y. T.
    Peelen, L. M.
    HEART, 2015, 101 (03) : 222 - 229
  • [9] On the importance of global cardiovascular risk assessment in people with type 2 diabetes
    Echouffo-Tcheugui, Justin B.
    Kengne, Andre P.
    PRIMARY CARE DIABETES, 2013, 7 (02) : 95 - 102
  • [10] Cardiovascular risk prediction in adults with type 1 diabetes: The Fremantle Diabetes Study
    Davis, Wendy A.
    Davis, Timothy M. E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (03) : E75 - E78